Q-omics provides the consensus-scored QRICH2 profile across patient tissues and cancer cell-line models. QRICH2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, QRICH2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, QRICH2 RNA expression shows 18,837 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, THCA, and THYM as cancer lineages where QRICH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for QRICH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes QRICH2 survival associations across molecular data types. QRICH2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible QRICH2 RNA expression–survival associations across cancer types. High QRICH2 expression shows unfavorable associations in COAD, ACC, KICH, MESO and LIHC, but favorable associations in HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for QRICH2 RNA expression.
This table summarizes QRICH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for QRICH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. QRICH2 shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, UCEC, KICH and BLCA. The THCA box plot shows higher QRICH2 RNA expression in normal versus tumor tissue (log2 FC = −1.368, t-test p < 0.001).
This table shows molecular features associated with QRICH2 in patient tissues and cancer cell lines. In patient samples, QRICH2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, QRICH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
